Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
84.37%
Operating Margin
49.07%
Net Margin
26.73%
Efficiency Metrics
Revenue per Expense Ratio
5.68
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
22.12%
EPS
3.4800000000
Balance Sheet Analysis
Current Ratio
17,665,319,000.0
Cash Ratio
12,202,765,000.0
Working Capital
$17.67B
Debt to Equity
0.24
Debt to Assets
2.06%
Equity Ratio
8.56%
Cash Flow Analysis
Operating Cash Flow Ratio
46.08%
Free Cash Flow Ratio
44.49%
CapEx to Revenue
1.58%
Dividends Paid
$252.01M
Stock Buybacks
No buybacks
Total Shareholder Returns
$252.01M
Cash Position Change
23.95%
Key Takeaways (2023 FY)
Revenue declined by 7.7938171618993%, indicating potential market challenges
Increased dividend payments by 9.33%
Detailed Growth Metrics
Core Performance
Revenue
-7.79%
Net Income
-28.26%
EPS
-30.26%
Operating Income
-19.70%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
45.76%
Operating Cash Flow
7.65%
Free Cash Flow
7.67%
Balance Sheet Health
Assets
0.13%
Debt
-73.85%
Book Value per Share
14.34%
Inventory
100.00%
Shareholder Returns
Dividends per Share
9.33%
Shares Outstanding
0.52%
Long Term Trends
3Y Revenue/Share
1.64%
5Y Revenue/Share
14.85%
3Y Dividend/Share
13.95%
5Y Dividend/Share
68.80%